EyePoint Pharmaceuticals, Inc.

NASDAQ:EYPT

Biotechnology

Healthcare
$2.99 +1.98%

+$0.26 today

Market cap
$250.69M
Beta
1.75
P/E (TTM)
-4.2
EPS (TTM)
-$3.16
52W Low $7.94High $19.11

Volume 2.75M

Average 0.95M

Income Statement

Follow revenue through to earnings.

Revenue

$31.37M

FY 2025 · Annual

-27.5% YoY

Operating Income

-$243.43M

FY 2025 · Annual

Net Income

-$231.96M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue36.94M41.4M46.02M43.27M31.37M
Cost of Revenue8.18M8.33M4.63M3.71M2.07M
Gross Profit28.76M33.08M41.39M39.56M29.31M
Gross Margin77.9%79.9%89.9%91.4%93.4%
Research & Development28.5M49.64M64.66M132.93M221.04M
Selling, General & Admin53.08M60.32M51.79M52.49M51.7M
Operating Expenses84.04M132.72M116.45M185.42M272.74M
Depreciation & Amortization2.77M2.45M464K1.54M2.31M
EBITDA(50.15M)(96.62M)(69M)(129.23M)(229.34M)
EBITDA Margin-135.8%-233.4%-149.9%-298.6%-731.1%
Operating Income(55.28M)(99.64M)(75.07M)(145.85M)(243.43M)
Operating Margin-149.6%-240.6%-163.1%-337.1%-776.0%
Interest Income292K2.13M6.95M15.09M11.75M
Interest Expense5.5M3.19M1.25M14K(33K)
Other Income / Expenses(3.14M)(2.62M)4.36M15.07M11.75M
Income Before Tax(58.42M)(102.25M)(70.71M)(130.78M)(231.68M)
Pre-Tax Margin-158.1%-247.0%-153.7%-302.2%-738.5%
Income Tax Expense0083K90K279K
Net Income(58.42M)(102.25M)(70.8M)(130.87M)(231.96M)
Net Margin-158.1%-247.0%-153.8%-302.4%-739.4%
EPS (Basic)(2.03)(2.74)(1.82)(2.32)(3.17)
EPS (Diluted)(2.03)(2.74)(1.82)(2.32)(3.17)
Weighted Avg Shares28.76M37.32M38.9M56.3M73.25M
Weighted Avg Shares (Diluted)28.76M37.32M38.9M56.3M73.25M

EYPT Earnings Waterfall · TTM

NASDAQ:EYPT · Revenue to Net Income

Key Ratios

EPS$-3.50
Gross Margin46.5%
Net Margin-7597.7%
P/E Ratio-4.0
P/S Ratio1299.3

Analysis

$7.6M of revenue converted into -$271.6M of net income for the selected period. Gross margin is 46.5% and net margin is -7597.7%, showing how much revenue survives after costs and taxes. EPS is $-3.50, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13G/ASC 13G/A filingOct 7, 2026
8-KCurrent reportSep 10, 2026
SC 13GSC 13G filingSep 8, 2026
4Statement of changes in beneficial ownershipAug 24, 2026
4Statement of changes in beneficial ownershipAug 18, 2026

How much revenue does EYPT generate?

EyePoint Pharmaceuticals, Inc. (EYPT) reported $31.37M of revenue in fiscal 2025.

Is EYPT profitable?

EyePoint Pharmaceuticals, Inc. (EYPT) reported -$231.96M of net income, with a net margin of -739.4%.